Form 8-K - Current report:
SEC Accession No. 0001711279-23-000003
Filing Date
2023-01-09
Accepted
2023-01-09 08:55:56
Documents
16
Period of Report
2023-01-09
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krys-20230109.htm   iXBRL 8-K 39813
2 EX-99.1 pressreleaseforworkiva.htm EX-99.1 7611
6 pressreleaseforworkiva001.jpg GRAPHIC 185363
7 pressreleaseforworkiva002.jpg GRAPHIC 216367
8 pressreleaseforworkiva003.jpg GRAPHIC 144036
  Complete submission text file 0001711279-23-000003.txt   930688

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT krys-20230109.xsd EX-101.SCH 1914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT krys-20230109_lab.xml EX-101.LAB 22164
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT krys-20230109_pre.xml EX-101.PRE 11598
10 EXTRACTED XBRL INSTANCE DOCUMENT krys-20230109_htm.xml XML 10347
Mailing Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203
Business Address 2100 WHARTON STREET SUITE 701 PITTSBURGH PA 15203 (412) 586-5830
Krystal Biotech, Inc. (Filer) CIK: 0001711279 (see all company filings)

EIN.: 821080209 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38210 | Film No.: 23516808
SIC: 2836 Biological Products, (No Diagnostic Substances)